Insider Selling: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells 47,031 Shares of Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 47,031 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $2.87, for a total value of $134,978.97. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mary E. Godwin also recently made the following trade(s):

• On Tuesday, September 17th, Mary E. Godwin sold 35,000 shares of Nautilus Biotechnology stock. The shares were sold at an average price of $2.85, for a total value of $99,750.00.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT opened at $2.85 on Friday. Nautilus Biotechnology, Inc. has a one year low of $2.19 and a one year high of $3.45. The business’s 50-day moving average price is $2.61 and its two-hundred day moving average price is $2.60. The company has a market capitalization of $357.42 million, a P/E ratio of -5.18 and a beta of 1.20.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, July 30th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the firm earned ($0.13) earnings per share. On average, equities analysts anticipate that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Nautilus Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its position in Nautilus Biotechnology by 35.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after buying an additional 4,239 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Nautilus Biotechnology by 66.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock worth $71,000 after acquiring an additional 9,624 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Nautilus Biotechnology by 11.2% during the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock valued at $328,000 after acquiring an additional 14,100 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Nautilus Biotechnology by 19.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after acquiring an additional 94,908 shares in the last quarter. Finally, Clarius Group LLC lifted its holdings in Nautilus Biotechnology by 2.7% in the 2nd quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares during the last quarter. Institutional investors and hedge funds own 50.71% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on NAUT shares. Guggenheim initiated coverage on Nautilus Biotechnology in a report on Thursday, June 27th. They issued a “buy” rating and a $6.00 target price for the company. Jefferies Financial Group started coverage on shares of Nautilus Biotechnology in a research note on Monday, June 3rd. They set a “hold” rating and a $3.00 target price for the company.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.